|
|
|
|
 |
Arena Pharmaceuticals to Present at the Bank of America 2008 Healthcare Conference |
| Companies mentioned in this article: |
|
Arena Pharmaceuticals |
|
| 5/9/2008 @ 6:24 AM
print this article -
email to a friend -
join our eNewsletter
|
 |
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) announced today that the company is scheduled to present at the Bank of America 2008 Healthcare Conference on May 14, 2008 at 5:20 p.m. Pacific Time (8:20 p.m. Eastern Time) at the Four Seasons Hotel in Las Vegas, Nevada. Dominic P. Behan, Ph.D., Arena's Senior Vice President and Chief Scientific Officer, is scheduled to provide an overview of the company, including its clinical development and discovery programs.
A live audio webcast of the presentation will be available under the investor relations section of Arena's website at www.arenapharm.com/. A replay of the presentation will be available until May 30, 2008. Please connect to Arena's website several minutes prior to the start of the webcast to ensure adequate time for any software download that may be necessary.
About Arena Pharmaceuticals
Arena is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases. Arena's most advanced drug candidate, lorcaserin, is being investigated in a Phase 3 clinical trial program for the treatment of obesity. Arena's broad pipeline of novel compounds target G protein-coupled receptors, an important class of validated drug targets, and includes compounds being evaluated independently and with partners, including Merck & Co., Inc. and Ortho-McNeil Pharmaceutical, Inc. |
| BioTech / BioMedical / Medical |
|
|
| |
| Thursday, July 17, 2008 |
 |
|
Ardea to Present Data on Lead HIV Candidate, RDEA806, at XVII International AIDS Conference Posted 7:24 AM PST
International Stem Cell Corporation and Novocell, Inc. Collaborate to Test Human Parthenogenetic Stem Cells for production of Pancreatic Islet Cells that may be useful in the Treatment of Diabetes Posted 6:54 AM PST
|
| |
| Wednesday, July 16, 2008 |
|
|
Immunosyn Announces Proposed Agreements for Distribution of the Biopharmaceutical SF-1019 in Utah Posted 3:10 PM PST
Raptor Pharmaceuticals Enters Collaboration Agreement with UC San Diego in Liver Disease Posted 6:06 AM PST
Inovio Biomedical’s First Proprietary DNA Vaccine Achieves 100% Protection Against Avian Flu in Pre-Clinical Testing Posted 5:57 AM PST
Cytori Receives U.S. Patent Allowance for Protecting Cosmetic & Reconstructive Surgery Product Line Posted 5:56 AM PST
Hollis-Eden Pharmaceuticals Commences Phase II Clinical Trial with TRIOLEX (HE3286) in Type-2 Diabetes Patients; Expands Sites to Accelerate Enrollment Posted 5:51 AM PST
Optimer Pharmaceuticals Announces Positive Results in Prulifloxacin Phase 3 Study Posted 5:50 AM PST
|
| |
| Tuesday, July 15, 2008 |
|
|
Favrille Announces Receipt of Nasdaq Letters Posted 5:09 PM PST
PURE Bioscience Announces Distribution Agreement With Orchem Corporation Posted 5:05 PM PST
South Miami Hospital Goes Live with CliniComp’s Essentris in All Perinatal Areas Posted 6:30 AM PST
|
| |
| Monday, July 14, 2008 |
|
|
Cytori Sells First European Union StemSource Bank; Industry Leading Biohellenika of Greece Acquires Exclusive Rights Posted 3:00 PM PST
Asymtek’s New DispenseJet DJ-9500 is up to Ten Times Faster than Needle Dispensers in High-Volume Underfill and LED Silicone Applications Posted 2:57 PM PST
Vical to Present Phase 1 Data for Vaxfectin -Formulated Pandemic Influenza DNA Vaccines Posted 6:03 AM PST
|
| |
| Friday, July 11, 2008 |
|
|
Invitrogen to Integrate Brendan Technologies’ Advanced Analytical Software into Protein Analysis Solutions Posted 7:44 AM PST
|
| |
| Thursday, July 10, 2008 |
|
|
PURE Bioscience Announces Brazilian Regulatory Approval for SDC-Based Disinfectant Posted 7:52 AM PST
|
| |
| Wednesday, July 9, 2008 |
|
|
Orexigen Initiates Second Phase Iib Empatic Trial on Schedule Posted 7:23 AM PST
Ardea Biosciences' Advances RDEA806 Into Phase 2a Proof-of-Concept Study for Gout Posted 7:23 AM PST
Arena Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis Posted 7:22 AM PST
Bio-Matrix Scientific Group, Inc. Announces Negotiations with Four Companies for Storage of Peripheral Blood Related Stem Cells Posted 6:58 AM PST
|
| |
| Tuesday, July 8, 2008 |
|
|
International Stem Cell Corporation Announces Collaboration with Michigan State University to Study Parthenogenetic Stem Cells Posted 7:47 AM PST
FDA Grants Invitrogen Premarket Approval of Breast Cancer Test Posted 7:42 AM PST
|
| |
| Monday, July 7, 2008 |
|
|
Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV Posted 3:06 PM PST
AutoGenomics INFINITI Analyzer Receives Artistic Design Award Posted 6:35 AM PST
|
|
|
|
|
|
FreshNews.com Jobs Change DAILY
We Have 5,000 + Job Listings! Open Your FREE Account
Employers or Job Searchers Get Started Now! Click Here
|
